Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Leslie Heller

Physician Assistant, Medical Powell, TN Physician Assistant

NPI 1720263213 CMS profile 10566630

7730 Dannaher Dr, Powell, TN 37849

Open in the dashboard

General payments

$11,318

681 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leslie Heller of Powell, TN is reported in the CMS Open Payments database as having received $11,318 across 681 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,740 186
2024 General $2,799 163
2023 General $2,061 111
2022 General $2,307 139
2021 General $1,411 82

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leslie Heller
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Leslie Heller were reported at $2,740. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Leslie Heller Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,411 $156 $41–$563 $132
2022 $2,307 $185 $55–$649 $149
2023 $2,061 $199 $58–$717 $160
2024 $2,799 $206 $62–$740 $164
2025 $2,740 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,956 141 payments
  2. Novartis Pharmaceuticals Corporation $1,470 66 payments
  3. Genzyme Corporation $988 34 payments
  4. Regeneron Healthcare Solutions, Inc. $959 35 payments
  5. Sun Pharmaceutical Industries Inc. $885 43 payments
  6. E.R. Squibb & Sons, L.L.C. $674 54 payments
  7. Janssen Biotech, Inc. $634 26 payments
  8. Lilly USA, LLC $608 44 payments
  9. Pfizer Inc. $481 37 payments
  10. Arcutis Biotherapeutics, Inc. $439 56 payments
  11. Other $2,225 145 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,813 674 payments
  2. Education $407 6 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $98 1 payment
Products named General payments · program years 2021–2025
  1. SKYRIZI $1,145 73 payments
  2. DUPIXENT Immunology $988 34 payments
  3. COSENTYX $779 31 payments
  4. SOTYKTU $674 54 payments
  5. TALTZ $608 44 payments
  6. DUPIXENT Inflammation And Immunology $533 20 payments
  7. TREMFYA $512 19 payments
  8. ILUMYA $509 31 payments
  9. EUCRISA $437 31 payments
  10. Zoryve $410 54 payments
  11. Other $5,835 385 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

616

Median for Physician Assistant: 241

Drug cost

$190,644

Median for Physician Assistant: $4,110

Branded share of claims

11.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 28 $122,145
Otezla Apremilast Brand 12 $59,122
Ketoconazole Generic 114 $1,867
Clobetasol Propionate Generic 39 $1,052
Triamcinolone Acetonide Generic 88 $985
Minoxidil Generic 84 $980
Fluorouracil Generic 16 $947
Doxycycline Hyclate Generic 44 $883
Fluocinonide Generic 12 $472
Clindamycin Phosphate Generic 18 $371

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$96,603

Of which drugs: $5,904

Medicare patients

416

Average age 75

Services billed

3,122

252 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 25%
Chronic kidney disease 23%
Depression 23%
Ischemic heart disease 20%
Cancer 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) J7308 Office 16 19 $5,887
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 27 $17

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $266
  • Regeneron Healthcare Solutions, Inc. $254
$519 28 —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $404
$404 — —
SKYRIZI
  • AbbVie, Inc. $238
$238 — —
Zoryve
  • Arcutis Biotherapeutics, Inc. $199
$199 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $192
$192 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

681 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record